These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23942819)

  • 1. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer.
    Yoshioka Y; Uehara K; Ebata T; Yokoyama Y; Mitsuma A; Ando Y; Nagino M
    Surg Today; 2014 Jul; 44(7):1300-6. PubMed ID: 23942819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.
    Li DB; Ye F; Wu XR; Wu LP; Chen JX; Li B; Zhou YM
    World J Gastroenterol; 2013 Feb; 19(5):761-8. PubMed ID: 23431050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
    Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients.
    Bège T; Lelong B; Viret F; Turrini O; Guiramand J; Topart D; Moureau-Zabotto L; Giovannini M; Gonçalves A; Delpero JR
    Ann Surg Oncol; 2009 Apr; 16(4):856-60. PubMed ID: 19156464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases.
    Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F
    Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab.
    Baxter NN; Fischer HD; Richardson DP; Urbach DR; Bell CM; Rochon P; Brade A; Earle CC
    Dis Colon Rectum; 2018 Mar; 61(3):306-313. PubMed ID: 29420426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.
    Starlinger P; Alidzanovic L; Schauer D; Maier T; Nemeth C; Perisanidis B; Tamandl D; Gruenberger B; Gruenberger T; Brostjan C
    Br J Cancer; 2012 Sep; 107(6):961-6. PubMed ID: 22850548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.
    Tsai HT; Marshall JL; Weiss SR; Huang CY; Warren JL; Freedman AN; Fu AZ; Sansbury LB; Potosky AL
    Ann Oncol; 2013 Jun; 24(6):1574-9. PubMed ID: 23429865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
    Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
    Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
    Kansal KJ; Dominici LS; Tolaney SM; Isakoff SJ; Smith BL; Jiang W; Brock JE; Winer EP; Krop IE; Golshan M
    Breast Cancer Res Treat; 2013 Sep; 141(2):255-9. PubMed ID: 24026859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
    BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
    J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.